Catalyst Pharmaceuticals, Inc.

327 articles with Catalyst Pharmaceuticals, Inc.

• Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

  9/9/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate in the hybrid in-person and virtual H.C. Wainwright 24th Annual Global Investment Conference.

• Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

  8/24/2022

  Catalyst Pharmaceuticals, Inc. today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at the upcoming Citi's 17th Annual BioPharma Conference.

• Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

  8/9/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the second quarter 2022 and provided a corporate update.

• Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET

  7/26/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its second quarter 2022 financial results after market close on Tuesday, August 9, 2022.

• Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences - May 17, 2022

  5/17/2022

  Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at two upcoming conferences.

• Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

  5/10/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the first quarter 2022 and provided a corporate update.

• Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

  4/25/2022

  Catalyst Pharmaceuticals, Inc. announced that it will release its first-quarter 2022 financial results after market close on Tuesday, May 10, 2022.

• Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

  3/16/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the fourth quarter and full year 2021 and provided a corporate update.

• Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

  3/11/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX),  and KYE Pharmaceuticals Inc. ("KYE"), today announced receipt of a favorable decision from the Federal Court of Canada (“Court”) setting aside for the second time the decision of Canada’s national healthcare regulatory agency, Health Canada, to approve Ruzurgi® (amifampridine) for Lambert-Eaton Myasthenic Syndrome ("LEMS") patients.

• Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET

  3/3/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2021 financial results after market close on Wednesday, March 16, 2022.

• Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

  3/2/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that the United States Patent and Trademark Office ("USPTO") has notified Catalyst that an additional patent covering FIRDAPSE®.

• Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

  2/7/2022

  Catalyst Pharmaceuticals, Inc. today provided preliminary 2021 fourth quarter and full year total revenue estimates, a forecast of 2022 total revenue expectations, and a corporate update.

• Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid

  2/3/2022

  Catalyst Pharmaceuticals, Inc. today reported that the District Court which heard Catalyst's Lawsuit against the FDA has entered summary judgment in favor of Catalyst.

• Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences

  1/4/2022

  Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst's Chairman and Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will participate in two upcoming investor conferences.

• 

  Clinical Catch-Up: December 6-10

  12/13/2021

  There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.

• Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan

  12/6/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that its collaboration partner DyDo Pharma ("DyDo") has initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of Catalyst's FIRDAPSE®.

• Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/15/2021

  Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29, 2021 through December 2, 2021.

• Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results

  11/9/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the third quarter ended September 30, 2021, and provided a corporate update.

• Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST

  10/25/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today announced that it will release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021.

• Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS

  9/30/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that it has received a positive decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the U.S. Food and Drug Administration’s (FDA) approval of another amifampridine product, Ruzurgi®